Table 2 A summary of the sources of the main dataset in the analysis
GWAS | Population | N | Source | ||
|---|---|---|---|---|---|
Exposure | |||||
Downstream biomarkers | |||||
LDL | EUR | 1,88,578 | Willer et al., 2013 | ||
SBP | EUR | 7,57,601 | Evangelou et al., 2018 | ||
DBP | EUR | 7,57,601 | Evangelou et al., 2018 | ||
CRP | EUR | 5,75,531 | Said et al., 2022 | ||
pQTL data | |||||
deCODE pQTLs | (4,907 proteins) | EUR | 35,559 | Ferkingstad et al., 2021 | |
UKB-PPP pQTLs | (2,923 proteins) | EUR | 54,219 | Sun et al., 2023 | |
Outcome | |||||
VaD | |||||
Meta-analysis | EUR | 7,008 / 899,672 | |||
FinnGen | EUR | 3,116 / 433,066 | Kurki et al., 2023 | ||
MEGAVCID | EUR | 3,892 / 466,606 | MEGAVCID et al., 2024 | ||
Neuroimaging features | |||||
WMH | EUR | 50,559 | Sargurupremraj et al., 2020 | ||
iFA | EUR | 31,125 | Taylor-Bateman et al., 2022 | ||
MD | EUR | 31,147 | Taylor-Bateman et al., 2022 | ||
LS | EUR | 6,030 / 248,929 | Traylor et al., 2021 | ||
Positive controls | |||||
CAD | EUR | 122,733 / 424,528 | van der Harst et al., 2018 | ||
Stroke | EUR | 67,162 / 454,450 | Malik et al., 2018 | ||
Heart failure | EUR | 14,262 / 471,898 | Sakaue et al., 2021 | ||
RA | EUR | 22,350 / 74,823 | Ishigake et al., 2022 | ||
